39432714 2023-12-31 39432714 2022-12-31 39432714 2023-01-01 fsa:ContributedCapitalMember 39432714 2023-01-01 fsa:RetainedEarningsMember 39432714 2023-12-31 fsa:ContributedCapitalMember 39432714 2023-12-31 fsa:RetainedEarningsMember 39432714 2023-01-01 fsa:AcquiredPatentsMember 39432714 2023-12-31 fsa:AcquiredPatentsMember 39432714 2023-01-01 fsa:InvestmentsInAssociatesMember 39432714 2022-01-01 fsa:InvestmentsInAssociatesMember 39432714 2023-12-31 fsa:InvestmentsInAssociatesMember 39432714 2022-12-31 fsa:InvestmentsInAssociatesMember 39432714 2023-12-31 1 fsa:AssociateMember 39432714 2023-01-01 fsa:OtherInvestmentsMember 39432714 2023-12-31 fsa:OtherInvestmentsMember 39432714 2023-01-01 2023-12-31 39432714 2023-01-01 2023-12-31 1 39432714 2023-01-01 2023-12-31 memberOfBoardIdentifier_executive_board_1 39432714 2023-01-01 2023-12-31 memberOfBoardIdentifier_board_of_director_1 39432714 2023-01-01 2023-12-31 memberOfBoardIdentifier_board_of_director_2 39432714 2023-01-01 2023-12-31 memberOfBoardIdentifier_board_of_director_3 39432714 2023-01-01 2023-12-31 memberOfBoardIdentifier_board_of_director_4 39432714 2023-01-01 2023-12-31 2 39432714 2022-01-01 2022-12-31 39432714 2023-01-01 2023-12-31 fsa:ContributedCapitalMember 39432714 2023-01-01 2023-12-31 fsa:RetainedEarningsMember 39432714 2023-01-01 2023-12-31 fsa:AcquiredPatentsMember 39432714 2023-01-01 2023-12-31 fsa:InvestmentsInAssociatesMember 39432714 2022-01-01 2022-12-31 fsa:InvestmentsInAssociatesMember 39432714 2023-01-01 2023-12-31 1 fsa:AssociateMember iso4217:DKK pure Årsrapport 33771231 PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab Strandvejen 44 2900 Hellerup 2023-01-01 2022-01-01 2023-12-31 2022-12-31 39432714 DeLiver Pharma ApS Tesdorpfsvej 12 5000 Odense C Odense 2018-03-09 Danske Bank PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab 33771231 Munkebjergvænget 1, 3. og 4. sal 5230 Odense M Denmark 63 14 42 00 odense@pwc.dk 2024-06-24 Niels Jonas Heilskov Graversen Regnskabsklasse B Andre erklæringer uden sikkerhed The Executive Board and Board of Directors have today considered and adopted the Annual Report of DeLiver Pharma ApS for the financial year 1 January - 31 December 2023. The Annual Report is prepared in accordance with the Danish Financial Statements Act. The Company complies with the exemption provisions governing the omission to have its Financial Statements audited. In our opinion the Financial Statements give a true and fair view of the financial position at 31 December 2023 of the Company and of the results of the Company operations for 2023. We recommend that the Annual Report be adopted at the Annual General Meeting. 2024-06-24 Odense C Niels Jonas Heilskov Graversen Manager Jens Kristian Damsgaard Chairman Holger Jon Møller Niels Jonas Heilskov Graversen Søren Kragh Moestrup To the Management of DeLiver Pharma ApS We have compiled the Financial Statements of DeLiver Pharma ApS for the financial year 1 January - 31 December 2023 on the basis of the Company’s accounting records and other information you have provided. The Financial Statements comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. We performed our work in accordance with ISRS 4410, Engagements to Compile Financial Information. Based on our professional expertise, we have assisted you with the preparation and presentation of the Financial Statements in accordance with the Danish Financial Statements Act. We have complied with relevant provisions of the Danish Act on Approved Auditors and Audit Firms and the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code), including the principles of integrity, objectivity, professional competence and due care. The Financial Statements and the accuracy and completeness of the information forming the basis of the compilation of the Financial Statements are your responsibility. As an engagement to compile financial information is not an assurance engagement, we are under no duty to verify the accuracy or completeness of the information you provided to us to compile the Financial Statements. Accordingly, we express no audit opinion or review opinion as to whether the Financial Statements have been prepared in accordance with the Danish Financial Statements Act. Odense 2024-06-24 PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab Mette Holy Jørgensen State Authorised Public Accountant mne34359 Peter Krogh Johansen State Authorised Public Accountant mne45868 118663 -17951 11380 11380 107283 -29331 107283 -29331 0 0 107283 -29331 107283 -29331 76285 87664 76285 87664 0 0 12500 12500 12500 12500 88785 100164 0 12257 0 12257 182575 8329 182575 20586 271360 120750 260000 260000 -43230 -150513 216770 109487 20538 11263 34052 0 54590 11263 54590 11263 271360 120750 260000 -150513 0 107283 260000 -43230 The company has contracted out its patents to OncoSpear ApS. The company's primary activity going forward is maintaining the patent portfolio, while active development of pharmaceuticals in the company is not pursued. The activities in the company are relatively few and the expenses can largely be passed on to the licensee. Furthermore it is expected that income will arise from the license agreement at a later stage. Until enough income is generated from the license agreement, the company's operation will be secured through capital contributions from the owners.On this basis it is the management's assessment that the capital is sufficient to be able to maintain operations. In accordance with this management submits the annual report under the assumption of the company's continued operation. The purpose of the company is the development and sale of technological products and other related business. 11380 11380 11380 11380 381223 381223 293558 11380 304938 76285 0 12500 0 -12500 0 0 0 0 Oncospear ApS Odense 11.48 7852765 -6694240 12500 12500 12500 Investments in associates are specified as follows: 0 0 There are no security and contingent liabilities at 31 December 2023. The Annual Report of DeLiver Pharma ApS for 2023 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B as well as selected rules applying to reporting class C. The accounting policies applied remain unchanged from last year. The Financial Statements for 2023 are presented in DKK. true 1 Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised cost are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement. Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably. Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably. Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below. Other external expenses comprise expenses for office expenses, etc. With reference to section 32 of the Danish Financial Statements Act, gross profit/loss is calculated as a summary of other operating income and other external expenses. Amortisation, depreciation and impairment losses comprise amortisation and impairment of intangible assets. Other operating income and other operating expenses comprise items of a secondary nature to the main activities of the Company, including gains and losses on the sale of intangible assets. Dividends from associates are recognised as income in the income statement when adopted at the General Meeting of the associate. However, dividends relating to earnings in the associate before it was acquired by the Parent Company are set off against the cost of the associate. Tax for the year consists of current tax for the year and changes in deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity transactions is recognised directly in equity. Patents and licences are measured at the lower of cost less accumulated amortisation and recoverable amount. Patents are amortised over the remaining patent period, and licences are amortised over the licence period; however not exceeding 12 year. The carrying amounts of intangible assets are reviewed on an annual basis to determine whether there is any indication of impairment other than that expressed by amortisation. If so, the asset is written down to its lower recoverable amount. Investments in associates are measured at cost. Where cost exceeds the recoverable amount, write-down is made to this lower value. Investments which are not traded in an active market are measured at the lower of cost and recoverable amount. Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Deferred income tax is measured using the balance sheet liability method in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes on the basis of the intended use of the asset and settlement of the liability, respectively. Deferred tax assets, including the tax base of tax loss carry-forwards, are measured at the value at which the asset is expected to be realised, either by elimination in tax on future earnings or by set-off against deferred tax liabilities within the same legal tax entity. Deferred tax is measured on the basis of the tax rules and tax rates that will be effective under the legislation at the balance sheet date when the deferred tax is expected to crystallise as current tax. Any changes in deferred tax due to changes to tax rates are recognised in the income statement or in equity if the deferred tax relates to items recognised in equity. Debts are measured at amortised cost, substantially corresponding to nominal value.